Navigation Links
Answerthink and LORENZ Life Sciences Group Announce Strategic,Alliance for the SAP Life Science Industry

MIAMI--(BUSINESS WIRE)--Jun 21, 2007 - Answerthink, Inc. (NASDAQ: ANSR) announced today that it has formed a strategic alliance with LORENZ Life Sciences Group for the distribution of LORENZ solutions in North America. Answerthink and LORENZ Life Sciences Group will serve midsize companies by integrating best practice submissions management solutions into Answerthink's Life Science solutions based on SAP technology.

Answerthink's pre-configured EzLifeSciences solutions are designed specifically to help midsize companies streamline new product development, automate manufacture reporting, and meet regulatory compliance requirements. LORENZ's solutions are geared specifically for submission assembly, review, publishing, validation and management for regulated environments within the life sciences industry as well as supporting the FDA mandate to submit electronically by the end of 2007.

"We are delighted to be able to tap into Answerthink's North American sales and service infrastructure, as well as their unrivaled SAP solution and deployment knowledge in the Life Sciences industry," said Wolfgang Witzel, President of LORENZ Life Sciences Group.

"This is a welcome confirmation of the global reputation we have acquired since 1989 in the field of submission management," added Mr. Witzel, stating that "the solutions we have provided to our customers and the results they have achieved are indeed - best practice."

According to Answerthink SAP Solutions Group Managing Director John McGrath, "We're delighted to be working with LORENZ. Our EzLifeSciences solutions are providing superior value for growing, innovative customers. LORENZ has successfully developed purpose-built solutions that can be integrated at ease which will only enhance our offerings to this industry."

About Answerthink

Answerthink, Inc. (www.answerthink.com) is a leading business and technology consulting firm that ena bles companies to achieve world-class business performance. By leveraging the comprehensive database of The Hackett Group, Answerthink's business and technology solutions help clients significantly improve performance and maximize returns on technology investments. Capabilities include benchmarking, business transformation, business applications, business intelligence, and offshore application development and support. Founded in 1997, Answerthink has offices throughout the United States and in Europe and Asia. Answerthink was named the SAP 2006 SME Partner of the Year.

About LORENZ Life Sciences Group

LORENZ Life Sciences Group (www.lorenz.cc) develops and markets software solutions for the Life Sciences market. LORENZ's solutions are geared specifically for submission assembly, review, publishing, validation and management. As the number one supplier of submission management systems in the world for US, European and Japanese submissions, LORENZ is currently the market leader in producing eCTDs. With over 100 installations in 20 countries, LORENZ has built a reputable customer base.

Copyright (C) 2007 Answerthink, Inc. All rights reserved. Answerthink and EzLifeSciences as well as their respective logos are trademarks or registered trademarks of Answerthink, Inc.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risks, uncertainties and other factors that may cause Answerthink's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. Factors that impact such forward-looking statements include, among others, the ability of the alliance or the products, services, or practices mentioned in this release to deliver the desired effect, our ability to effectively integrate acquisitions into our operations, our ability to attract additional business, our ability to effectively market and sell our transformation advisory product offerings and other services, the timing of projects and the potential for contract cancellations by our customers, changes in expectations regarding the information technology industry, our ability to attract and retain skilled employees, possible changes in collections of accounts receivable, risks of competition, price and margin trends, changes in general economic conditions and interest rates as well as other risks detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2006 filed with the Securities and Exchange Commission. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Answerthink
Marjorie Constable, 610-234-5678
mconstable@answerthink.com
or
LORENZ Life Sciences Group
Yaprak Eisinger, 914-310-0097
yeisinger@lorenz.cc


'"/>




Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
7. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
10. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
11. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  The leader in accelerated orthodontics, ... Sam Daher , Manal Ibrahim , ... Couchat will be the featured microlecture presenters at the ... Association of Orthodontists (AAO) Annual Session, April 21-25, 2017. ... microlectures beginning daily at 11:20 a.m. On the opening ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, a ... GSP 301, an investigational fixed-dose combination of mometasone ... administered twice-daily as a nasal spray being studied ... results are from a recently completed Phase 3 ... 301 combination therapy versus mometasone, olopatadine or placebo. ...
(Date:3/29/2017)... , March 29, 2017 ... a report, which provides an exhaustive study of ... study, nearly 242 companies are functional in this ... competitive. With the leading companies, such as GlaxoSmithKline ... LP, focusing aggressively on various marketing strategies to ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower ... college students who have participated in the program every summer. The 2017 Serve, ... applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I have ...
(Date:3/29/2017)... Rouge, Louisiana (PRWEB) , ... March 29, 2017 ... ... HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers ... at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the ...
(Date:3/29/2017)... Mt. Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... her patients on early orthodontic treatment and accepting new pediatric patients, with or without ... can help young patients have a better orthodontic outcome and experience. When patients receive ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... Ca (PRWEB) , ... March 29, 2017 , ... Immunotherapy ... a growing number of cancers and is touted to be the next revolution in ... thus far, has been in the form of immune checkpoint inhibitors such as PD-1 ...
Breaking Medicine News(10 mins):